Meridiem Investment Management’s AbbVie ABBV Stock Holding History

Meridiem Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$239K	Sell	1,100 -95	-8%	-$21.1K	0.01%	35
2025 Q4	$273K	Buy	1,195 +695	+139%	+$158K	0.01%	36
2025 Q3	$116K	Hold	500	–	–	﹤0.01%	43
2025 Q2	$92.8K	Sell	500 -685	-58%	-$127K	﹤0.01%	43
2025 Q1	$248K	Sell	1,185 -750	-39%	-$146K	﹤0.01%	37
2024 Q4	$344K	Hold	1,935	–	–	0.01%	33
2024 Q3	$382K	Hold	1,935	–	–	0.01%	35
2024 Q2	$332K	Hold	1,935	–	–	0.01%	35
2024 Q1	$352K	Hold	1,935	–	–	0.01%	35
2023 Q4	$300K	Buy	1,935 +750	+63%	+$109K	0.01%	43
2023 Q3	$177K	Hold	1,185	–	–	﹤0.01%	43
2023 Q2	$160K	Sell	1,185 -215	-15%	-$31.5K	﹤0.01%	48
2023 Q1	$223K	Hold	1,400	–	–	0.01%	42
2022 Q4	$226K	Hold	1,400	–	–	0.01%	45
2022 Q3	$188K	Hold	1,400	–	–	0.01%	47
2022 Q2	$215K	Hold	1,400	–	–	0.01%	47
2022 Q1	$227K	Hold	1,400	–	–	0.01%	47
2021 Q4	$190K	Hold	1,400	–	–	0.01%	52
2021 Q3	$151K	Hold	1,400	–	–	0.01%	57
2021 Q2	$158K	Hold	1,400	–	–	0.01%	58
2021 Q1	$151K	Sell	1,400 -366	-21%	-$39.1K	0.01%	56
2020 Q4	$189K	Buy	+1,766	New	+$170K	0.01%	48

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meridiem Investment Management's ABBV Position: Q1 2026 in Review

Meridiem Investment Management reduced its AbbVie (ABBV) stake by 7.9% in Q1 2026, selling an estimated $21.1K and leaving 1,100 shares worth $239K. The position accounts for 0.01% of the portfolio, ranked #35.

Meridiem Investment Management first reported a position in ABBV in Q4 2020 and has held it in 22 quarters since. The position peaked at $382K in Q3 2024. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Meridiem Investment Management held 1,100 shares of AbbVie worth $239K as of Q1 2026.
Meridiem Investment Management sold 95 AbbVie shares in Q1 2026, an estimated $21.1K.
AbbVie made up 0.01% of Meridiem Investment Management's portfolio in Q1 2026, its #35 holding.
Meridiem Investment Management first reported a position in AbbVie in Q4 2020 and has held it in 22 quarters since.
Meridiem Investment Management's AbbVie position peaked at $382K in Q3 2024.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Meridiem Investment Management's 13F filing for Q1 2026, filed 12 May 2026.